Navigation Links
Herpes virus infection drives HIV infection among non-injecting drug users in New York
Date:6/27/2014

HIV and its transmission has long been associated with injecting drug use, where hypodermic syringes are used to administer illicit drugs. Now, a newly reported study by researchers affiliated with New York University's Center for Drug Use and HIV Research (CDUHR) in the journal PLOS ONE, shows that HIV infection among heterosexual non-injecting drug users (no hypodermic syringe is used; drugs are taken orally or nasally) in New York City (NYC) has now surpassed HIV infection among persons who inject drugs.

The study, "HSV-2 Co-Infection as a Driver of HIV Transmission among Heterosexual Non-Injecting Drug Users in New York City," was conducted among drug users entering the Mount Sinai Beth Israel drug treatment programs in NYC. The researchers found that HIV infection among non-injecting drug users doubled over the last two decades, from 7% infected in the late 1990s (n= 785) to 14% (n=1764) currently. During this same time-frame, HIV infection among persons who inject drugs fell to 10%.

The increased efficiency for transmitting HIV occurs even when persons with herpes simplex virus 2 (HSV-2) are between outbreaks, as herpes increases both susceptibility to and transmissibility of HIV. More than half of the non-injecting drug users in the study were infected with HSV-2.

"Heterosexual intercourse is usually not very efficient for transmitting HIV, but the efficiency of heterosexual transmission nearly triples in the presence of herpes simplex virus type 2," notes the study's lead author, Don Des Jarlais, PhD, Deputy Director, Research Methods and Infectious Diseases Cores, Center for Drug Use and HIV Research (CDUHR) and Professor of Psychiatry and of Preventive Medicine at Mount Sinai Beth Israel. "In New York City, we have done an excellent job of reducing HIV among persons who inject drugs and we must now put more efforts into reducing sexual transmission associated with non-injecting drug use."

The study concludes that an increase in HIV infection among these non-injecting drug users is better considered as an increase in HSV- 2/HIV co-infection rather than simply an increase in HIV prevalence. Additional interventions (such as treatment as prevention and pre-exposure prophylaxis) are needed to reduce further HIV transmission from HSV-2/HIV co-infected non-injecting drug users.

The City Department of Health and Mental Hygiene has initiated a program "treatment as prevention," in which HIV infected persons are given anti-viral medications to both protect their own health and to reduce the chances that they will transmit HIV to others. There are also new federal recommendations to provide anti-retroviral medications to HIV uninfected persons at high risk for becoming infected.

"If we can implement these programs on a large scale, we should be able to control sexual transmission of HIV in the city, and achieve the goal of an "End to the AIDS Epidemic," said Dr. Des Jarlais.


'/>"/>

Contact: Christopher James
christopher.james@nyu.edu
212-998-6876
New York University
Source:Eurekalert

Related biology news :

1. Herpesviruses undercover
2. Herpes-loaded stem cells used to kill brain tumors
3. New research on inherited herpesvirus may have implications for transplantation
4. Herpes infections: Natural killer cells activate hematopoiesis
5. How herpesvirus invades nervous system
6. Einstein study reveals new approach for stopping herpes infections
7. Novel treatment approach for bladder pain using a herpes simplex virus vector reported
8. Princeton researchers identify unexpected bottleneck in the spread of herpes simplex virus
9. How and why herpes viruses reactivate to cause disease
10. USAMRIID research sheds light on how deadly lassa virus infects cells
11. New infections cause dormant viruses to reactivate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... for financial services, but it also plays a fundamental part ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
Breaking Biology News(10 mins):
(Date:5/4/2016)... ... May 04, 2016 , ... The Children’s Tumor Foundation announced its ... tumors to grow on nerves throughout the body. It affects 1 in 3,000 people ... events held during the month of May, as well as online activities, Neurofibromatosis Awareness ...
(Date:5/4/2016)... 2016 According to a new ... - Global Industry Analysis, Size, Share, Growth, Trends, and ... to expand at a CAGR of 17.1% from 2016 ... Metabolomics is the extensive study of small ... or organisms. Together, these small molecules and their interactions ...
(Date:5/4/2016)... ... ... PBI-Gordon Corporation is pleased to announce Doug Obermann has been promoted to ... PBI-Gordon in February 1988, after finishing his masters in agronomy from Iowa State University. ... to national product manager, to helping develop, name and launch many of the most ...
(Date:5/4/2016)... York, NY (PRWEB) , ... May 04, 2016 ... ... has leveraged recent innovations in biotechnology to help treat hormonal and stress related ... loss, Nutrafol® has captured the hearts of key opinion leaders in the medical ...
Breaking Biology Technology: